200-year-old death math could transform how protein drugs are built
Why This Matters
Actuaries have long used a statistical trick — separating the different ways something can fail — to predict human mortality, but researchers are now asking whether this same framework could decode how next-generation protein drugs fall apart inside the body. The surprising twist is that fixing one vulnerability in these drugs could mathematically guarantee another weakness gets worse, meaning the entire industry's approach to testing stability may be built on a blind spot. If these ideas hold up, borrowing an insurance mathematician's toolbox could reshape how AI-designed medicines are approved — and which ones actually make it to patients.
Compare Hypotheses
The Dominant Competing Risk Theorem -- Optimizing One Failure Mode Provably Accelerates Another
Fix one way a protein drug breaks, and you mathematically guarantee another weakness gets worse.
Impact: If confirmed experimentally, this theorem could fundamentally reshape how protein drugs are designed and tested — pus...
Competing-Risk Cumulative Incidence Functions as a Unified Protein Therapeutic Lifetime Predictor
A survival statistics framework borrowed from actuaries could predict exactly how—and when—engineered protein drugs will break down in the body.
Impact: If confirmed, this framework could fundamentally change how AI-designed protein therapeutics are evaluated and optimi...
Competing Risks Censoring Correction for Immunogenicity -- Anti-Drug Antibodies as Interval-Censored Competing Risk
Fixing a hidden flaw in drug safety testing: fast-failing proteins mask their immune risks until it's too late.
Impact: If confirmed, this framework could fundamentally change how biopharmaceutical companies and regulators assess the saf...
Nelson-Aalen Cumulative Hazard Decomposition Reveals Hidden Failure Modes in Accelerated Stability Studies
Splitting protein drug degradation into its hidden failure modes could make shelf-life predictions far more accurate.
Impact: If confirmed, this method could reshape how the pharmaceutical industry — and regulators like the FDA — tests and app...
All Hypotheses
Click any hypothesis to see the full mechanism, evidence, and test protocol.
The Dominant Competing Risk Theorem -- Optimizing One Failure Mode Provably Accelerates Another
PASSFix one way a protein drug breaks, and you mathematically guarantee another weakness gets worse.
Competing-Risk Cumulative Incidence Functions as a Unified Protein Therapeutic Lifetime Predictor
PASSA survival statistics framework borrowed from actuaries could predict exactly how—and when—engineered protein drugs will break down in the body.
Competing Risks Censoring Correction for Immunogenicity -- Anti-Drug Antibodies as Interval-Censored Competing Risk
CONDITIONALFixing a hidden flaw in drug safety testing: fast-failing proteins mask their immune risks until it's too late.
Nelson-Aalen Cumulative Hazard Decomposition Reveals Hidden Failure Modes in Accelerated Stability Studies
CONDITIONALSplitting protein drug degradation into its hidden failure modes could make shelf-life predictions far more accurate.